No products in the cart
CJC-1295 with DAC – Peptide Review
CJC-1295 is a synthetically modified and tetra-substituted form of growth hormone-releasing hormone (GHRH129). Due to substituting four amino acids from the core unit, the CJC-1295 with DAC peptide is more resistant to cleavage by proteolytic enzymes. CJC-1295 significantly increases plasma growth hormone (GH) and insulin-like growth factor 1 (IGF1) levels in animals and humans. The estimated half-life of this substance is about 6-8 days in humans. Multiple doses of CJC-1295 with DAC maintain elevated IGF1 levels in humans for up to 28 days.
It contains a chain of 30 amino acids, a molecular weight of 3368.7, and a molecular formula of C152H252N44O42. CJC-1295 acts by binding to serum albumin-a, and the addition of the Drug Affinity Complex or DAC prolongs the half-life of CJC-1295 and the duration of action in animal subjects.
Mechanism of Action of CJC-1295 with DAC
Studies of the CJC-1295 with DAC peptide in animal subjects show how this peptide functions by interacting with growth hormone (GH), insulin-like growth factor 1 (IGF1), and the enzyme dipeptidyl aminopeptidase IV (DPPIV) is showing.
DPPIV is an antigenic enzyme involved in signal transduction, apoptosis or programmed cell death, and immune system regulation. It also directly affects the half-life of growth hormone (GH), shortening it to just under 7 minutes.
CJC-1295 with DAC reduces the production of the DPPIV enzyme. This reduction extends the half-life of GH and IGF1 and creates a feedback loop that lasts more than seven days after administration to animal subjects.
The mechanism of action of the CJC-1295 peptide dramatically prolongs the half-life of growth hormone (GH) and insulin-like growth factor 1 (IGF1) and dramatically extends the processes involving GH and IGF1. Some of these effects are below.
Increase the Protein Synthesis. The extended half-life of GH and IGF1 caused by CJC-1295 increases the rate of protein synthesis in experimental animals. This result will significantly increase muscle size and muscle mass over time.
Increase the Bone Density. Increased protein synthesis plays a role in increasing bone density. Experimental animals have shown that bone is rich in minerals per square centimeter after administration of CJC-1295.
Decrease the Body Fat. The effects of CJC-1295 on DPPIV and GHRH have also played an essential role in lipolysis or body fat breakdown. Researchers found that subjects increased lipolysis, reducing their overall body fat.
It Improves Quality of Sleep. There is no way to measure the quality of sleep in animals quantitatively. Still, this effect implies that increased deep sleep also compensates for increased protein synthesis rates.
CJC-1295 Side Effects
One of the main reasons CJC-1295 is so prevalent in the anti-aging battle is that it has a relatively low incidence of side effects. Most people tolerate CJC-1295 very well, and the side effects are generally mild. The most common side effect was the reaction at the injection site. It is usually skin discomfort or mild pain at the injection site. In general, people taking the medications do not stop using them because of side effects, and most tests did not find any significant side effects. Common side effects of CJC-1295 observed in clinical trials and trials are:
● Sensitivity, soreness, or pain at the injection site
● Flu-like symptoms
● Headache and Nausea
● Hiver or other skin reactions
● Difficulty swallowing
CJC-1295 without DAC vs. CJC-1295 with DAC
When purchasing peptides, it is crucial to understand their effects and how the addition of certain compounds changes their properties. The market offers a variety of options for those looking to buy peptides.
The unchanged CJC-1295 has shown the above effects, but adding a DAC improves the overall impact. Animal studies also show that CJC-1295 with DAC has a higher protein synthesis effect, faster recovery time, higher bone density increase, and higher muscle growth effect than unmodified CJC-1295.
Disclaimer: The products mentioned are not for human or animal consumption. All the information shared in this article is for educational purposes only.
Dr. Usman (BSc, MBBS, MaRCP) completed his studies in medicine at the Royal College of Physicians, London. He is an avid researcher with more than 30 publications in internationally recognized peer-reviewed journals. Dr. Usman has worked as a researcher and a medical consultant for reputable pharmaceutical companies such as Johnson & Johnson and Sanofi.